If you are interested in antisense oligonucleotides and want to learn more, we recommend the following literature:

  • Beierlein, J.M., McNamee, L.M., Ledley, F.D., 2017.
    As Technologies for Nucleotide Therapeutics Mature, Products Emerge. Molecular Therapy - Nucleic Acids 9, 379–386.

  • Crooke, S.T., Wang, S., Vickers, T.A., Shen, W., Liang, X., 2017.
    Cellular uptake and trafficking of antisense oligonucleotides. Nature Biotechnology 35, 230–237.

  • Evers, M.M., Toonen, L.J.A., van Roon-Mom, W.M.C., 2015.
    Antisense oligonucleotides in therapy for neurodegenerative disorders. Advanced Drug Delivery Reviews 87, 90–103.

  • Geary, R.S., Norris, D., Yu, R., Bennett, C.F., 2015.
    Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Advanced Drug Delivery Reviews 87, 46–51.

  • Hagedorn, P.H., Persson, R., Funder, E.D., Albæk, N., Diemer, S.L., Hansen, D.J., Møller, M.R., Papargyri, N., Christiansen, H., Hansen, B.R., Hansen, H.F., Jensen, M.A., Koch, T., 2018.
    Locked nucleic acid: modality, diversity, and drug discovery. Drug Discovery Today 23, 101–114.

  • Jaschinski F., Korhonen H., Janicot M. 2015.
    Design and Selection of Antisense Oligonucleotides Targeting Transforming Growth Factor Beta (TGF-β) Isoform mRNAs for the Treatment of Solid Tumors. In: Walther W., Stein U. (eds) Gene Therapy of Solid Cancers. Methods in Molecular Biology, vol 1317. Humana Press, New York, NY

  • Juliano, R.L., Ming, X., Carver, K., Laing, B., 2014.
    Cellular Uptake and Intracellular Trafficking of Oligonucleotides: Implications for Oligonucleotide Pharmacology. Nucleic Acids Therapeutics 24, 2.

  • Sewing, S., Roth, A.B., Winter, M., Dieckmann, A., Bertinetti-Lapatki, C., Tessier, Y., McGinnis, C., Huber, S., Koller, E., Ploix, C., Reed, J.C., Singer, T., Rothfuss, A., 2017. Assessing single-stranded oligonucleotide drug-induced effects in vitro reveals key risk factors for thrombocytopenia. PLOS ONE 12, e0187574.

  • Shen, X., Corey, D.R., 2017.
    Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. Nucleic Acids Research.

  • Stanton, R., Sciabola, S., Salatto, C., Weng, Y., Moshinsky, D., Little, J., Walters, E., Kreeger, J., DiMattia, D., Chen, T., 2012.
    Chemical modification study of antisense gapmers. Nucleic acid therapeutics 22, 344–359.

  • Stein, C.A., Castanotto, D., 2017.
    FDA-Approved Oligonucleotide Therapies in 2017. Molecular Therapy 25, 1069–1075.

  • Stein, C.A., Hansen, J.B., Lai, J., Wu, S., Voskresenskiy, A., H⊘g, A., Worm, J., Hedtjärn, M., Souleimanian, N., Miller, P., Soifer, H.S., Castanotto, D., Benimetskaya, L., Ørum, H., Koch, T., 2010.
    Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Research 38, e3–e3.

  • Zhang, Y., Qu, Z., Kim, S., Shi, V., Liao, B., Kraft, P., Bandaru, R., Wu, Y., Greenberger, L.M., Horak, I.D., 2011.
    Down-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonucleotides without transfection. Gene therapy 18, 326.